CERO Therapeutics (CEROW) Furnishes Investor Presentation Sep 2025

CERO Therapeutics Holdings, Inc. filed a Form 8-K reporting that it furnished an Investor Presentation dated September 2025 as Exhibit 99.1.

Rhea-AI Filing Summary

CERO Therapeutics Holdings, Inc. filed a Form 8-K reporting that it furnished an Investor Presentation dated September 2025 as Exhibit 99.1. The company explicitly states that information on its website is not incorporated or made part of the filing. The submission was signed by Chris Ehrlich, Chief Executive Officer. No financial results, transactions, or forward-looking guidance are included in the disclosed text; the filing functions to furnish corporate presentation materials to the SEC record rather than to amend prior disclosures.

Positive

• Investor Presentation furnished as Exhibit 99.1, increasing public availability of company materials
• Clear statement that website content is not incorporated, reducing ambiguity about disclosure scope

Negative

• None.

Insights

Investor Relations Analyst

Company furnished an investor presentation to the SEC without incorporating website content.

The filing confirms an Investor Presentation dated September 2025 was furnished as Exhibit 99.1 and clarifies the company website content is not incorporated by reference. This is an administrative disclosure that places presentation materials on the SEC public record.

Because no financial metrics, transactions, or material agreements are included in the text provided, monitor the attached Exhibit 99.1 for any substantive updates or figures that could affect valuation or near-term investor expectations.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

What did CERO Therapeutics (CEROW) file in this Form 8-K?

The company furnished an Investor Presentation dated September 2025 as Exhibit 99.1 and noted that website content is not incorporated by reference.

Is the company website information incorporated into the filing for CEROW?

No. The filing explicitly states that the information on the company's website is not included or incorporated by reference.

Who signed the Form 8-K for CERO Therapeutics?

The Form 8-K was signed by Chris Ehrlich, Chief Executive Officer.

Does the 8-K include financial results or material transactions?

No. The provided text contains no financial data, transactions, or earnings information—only the furnishing of an investor presentation.

Where can investors find the presentation mentioned in the filing?

The presentation is furnished as Exhibit 99.1 to the Form 8-K; review the exhibit for the presentation's full content and any material details.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/22/2025 - 04:10 PM Learn about SEC filing dates

false 0001870404 0001870404 2025-09-22 2025-09-22 0001870404 CERO:CommonStockParValue0.0001PerShareMember 2025-09-22 2025-09-22 0001870404 CERO:WarrantsEachWarrantExercisableForOneTwothousandthOfShareOfCommonStockMember 2025-09-22 2025-09-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or Section 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 22, 2025

CERO THERAPEUTICS HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-40877		81-4182129
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(I.R.S. Employer Identification Number)

201 Haskins Way, Suite 230, South San Francisco, CA		94080
(Address of principal executive offices)		(Zip Code)

(650) 407-2376

Registrant’s telephone number, including area code

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		CERO		Nasdaq Capital Market
Warrants, each warrant exercisable for one two-thousandth of a share of Common Stock		CEROW		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On September 22, 2025, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), updated its corporate presentation, which it plans to use in meetings with investors, analysts and others. The presentation can be found on the Company’s website, www.cero.bio. The information set forth on the Company’s website is not included or incorporated by reference herein. A copy of this corporate presentation is furnished hereto as Exhibit 99.1.

The information in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Investor Presentation, dated September 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CERO THERAPEUTICS HOLDINGS, INC.
Dated: September 22, 2025	By:	/s/ Chris Ehrlich
	Name:	Chris Ehrlich
	Title:	Chief Executive Officer

2